???global.info.a_carregar???
Cong Tang. Completed the Doktor (PhD) in Clinical Medicine in 2019/12/10 by Xi'an Jiaotong University, Master in Clinical Medicine in 2017/06/30 by Xi'an Jiaotong University, Candidatus in Pharmacology and Chemical Biology in 2019/10/10 by Emory University and Bachelor in Clinical Medicine in 2016/06/30 by Xi'an Jiaotong University. Is postdoctoral researcher in Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes. Published 11 articles in journals. Has 2 patent(s) registered. Works in the area(s) of Medical and Health Sciences with emphasis on Basic Medicine with emphasis on Pharmacology and pharmacy, Medical and Health Sciences with emphasis on Clinical Medicine, Natural sciences with emphasis on Biological Sciences with emphasis on Biochemistry and Natural sciences with emphasis on Biological Sciences with emphasis on Cell Biology.
Ler resumo completo ↓
Identificação

Identificação pessoal

Nome completo
Cong Tang

Nomes de citação

  • Tang, Cong

Identificadores de autor

Ciência ID
6213-029E-F967
ORCID iD
0000-0003-1661-6793

Endereços de correio eletrónico

  • cong.tang@medicina.ulisboa.pt (Profissional)
  • tangc1025@gmail.com (Pessoal)

Telefones

Telemóvel
  • 911917380 (Pessoal)

Domínios de atuação

  • Ciências Médicas e da Saúde - Medicina Básica - Farmacologia e Farmácia
  • Ciências Médicas e da Saúde - Medicina Clínica
  • Ciências Naturais - Ciências Biológicas - Bioquímica
  • Ciências Naturais - Ciências Biológicas - Biologia Celular
  • Ciências Naturais - Ciências Biológicas - Biologia Molecular

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Inglês Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1)
Chinês (Idioma materno)
Português Utilizador elementar (A1) Utilizador elementar (A1) Utilizador elementar (A1) Utilizador elementar (A1) Utilizador elementar (A1)
Formação
Grau Classificação
2017/09/01 - 2019/12/10
Concluído
 Clinical Medicine (Doktor (PhD))
Xi'an Jiaotong University, China
2017/07/10 - 2019/10/10
Concluído
 Pharmacology and Chemical Biology (Candidatus)
Emory University, Estados Unidos
2016/09/01 - 2017/06/30
Concluído
 Clinical Medicine (Master)
Xi'an Jiaotong University, China
2011/09/01 - 2016/06/30
Concluído
 Clinical Medicine (Bachelor)
Xi'an Jiaotong University, China
Percurso profissional

Ciência

Categoria Profissional
Instituição de acolhimento 		Empregador
2017/07/10 - 2019/10/10 Investigador visitante (Investigação) Emory University, Estados Unidos
2013/07/13 - 2013/08/15 Investigador visitante (Investigação) The University of British Columbia, Canadá

Cargos e Funções

Categoria Profissional
Instituição de acolhimento 		Empregador
2020/09/15 - Atual postdoctoral researcher Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal

Outros

Categoria Profissional
Instituição de acolhimento 		Empregador
2016/09/01 - 2017/07/04 Intern doctor Xi'an Jiaotong University Medical College First Affiliated Hospital, China
Projetos

Bolsa

Designação Financiadores
2022/01/17 - 2025/01/16 SmartBox: Engineering the first generation of ROS responsive ADCs
PTDC/QUI-OUT/3989/2021
Investigador Pós-doutorado
Em curso
2017/07/04 - 2019/10/20 MD&PhD exchange program
NA
Bolseiro de Doutoramento
Emory University, Estados Unidos

Xi'an Jiaotong University, China
Concluído

Projeto

Designação Financiadores
2021/05/01 - 2023/04/30 E3-hijacking molecular glues of RNA binding protein IGF2BP1 in ovarian cancer
GA101038053
Bolseiro de Pós-Doutoramento
Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal
Em curso
2020/09/15 - 2021/04/30 Site-selelctive protein-modification chemistries for antibody-drug conjugates (ADCs)
SIMICA-GA 852985
Investigador Pós-doutorado
Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal
Concluído
Produções

Publicações

Artigo em conferência
  1. Tang, Cong. "THER-17. BRAF-V600E DEGRADATION AS A THERAPEUTIC STRATEGY IN BRAF-V600E MUTANT GLIOMAS.". 2019.
    https://doi.org/10.1093/neuonc/noz036.224
Artigo em revista
  1. Buwei Huang; Mohamad Abedi; Green Ahn; Brian Coventry; Isaac Sappington; Cong Tang; Rong Wang; et al. "Designed endocytosis-inducing proteins degrade targets and amplify signals". Nature (2024): https://doi.org/10.1038/s41586-024-07948-2.
    10.1038/s41586-024-07948-2
  2. Cong Tang; Rui Traquete; Elizabeth Henderson; João Conde; Sara Picaud; Panagis Filippakopoulos; Gonçalo Bernardes. "Abstract 5779: Enhancing selectivity and overcoming tissue-specific toxicity in drug discovery: A novel BET inhibitor with targeted delivery for prostate cancer treatment". Cancer Research (2024): http://dx.doi.org/10.1158/1538-7445.am2024-5779.
    10.1158/1538-7445.am2024-5779
  3. Cong Tang; Patrícia Corredeira; Sandra Casimiro; Wesley Sukdao; Luís Costa; Emma Yates; Gonçalo Bernardes. "Abstract 1268: Immune activation characterization via amino acid concentration signatures for multi-cancer early detection and CDKi treatment response prediction". Cancer Research (2024): http://dx.doi.org/10.1158/1538-7445.am2024-1268.
    10.1158/1538-7445.am2024-1268
  4. Maria Rebelo; Cong Tang; Ana R Coelho; Carlos Labão-Almeida; Matthias M Schneider; Laurie Tatalick; Pedro Ruivo; et al. "De Novo Human Angiotensin-Converting Enzyme 2 Decoy NL-CVX1 Protects Mice From Severe Disease After Severe Acute Respiratory Syndrome Coronavirus 2 Infection". The Journal of Infectious Diseases (2023): http://dx.doi.org/10.1093/infdis/jiad135.
    10.1093/infdis/jiad135
  5. Sigitas Mikutis; Maria Rebelo; Eliza Yankova; Muxin Gu; Cong Tang; Ana R. Coelho; Mo Yang; et al. "Proximity-Induced Nucleic Acid Degrader (PINAD) Approach to Targeted RNA Degradation Using Small Molecules". ACS Central Science (2023): http://dx.doi.org/10.1021/acscentsci.3c00015.
    10.1021/acscentsci.3c00015
  6. Leeroy Baron; Justine Hadjerci; Leishemba Thoidingjam; Marina Plays; Romain Bucci; Nolwenn Morris; Sebastian Müller; et al. "PSL Chemical Biology Symposia Third Edition: A Branch of Science in its Explosive Phase". ChemBioChem (2023): http://dx.doi.org/10.1002/cbic.202300093.
    10.1002/cbic.202300093
  7. Cong Tang; Ana R. Coelho; Maria Rebelo; Hannah Kiely-Collins; Tânia Carvalho; Gonçalo J. L. Bernardes. "A Selective SARS-CoV-2 Host-Directed Antiviral Targeting Stress Response to Reactive Oxygen Species". ACS Central Science 9 1 (2023): 109-121. http://dx.doi.org/10.1021/acscentsci.2c01243.
    10.1021/acscentsci.2c01243
  8. Xiulei Mo; Qiankun Niu; Andrey A. Ivanov; Yiu Huen Tsang; Cong Tang; Changfa Shu; Qianjin Li; et al. "Systematic discovery of mutation-directed neo-protein-protein interactions in cancer". Cell (2022): https://doi.org/10.1016/j.cell.2022.04.014.
    10.1016/j.cell.2022.04.014
  9. Cong Tang; Qiankun Niu; Danielle Cicka; Yuhong Du; Xiulei Mo; Haian Fu. "A time-resolved fluorescence resonance energy transfer screening assay for discovery of protein-protein interaction modulators". STAR Protocols 2 3 (2021): 100804-100804. https://doi.org/10.1016/j.xpro.2021.100804.
    10.1016/j.xpro.2021.100804
  10. Cong Tang; Xiulei Mo; Qiankun Niu; Alafate Wahafu; Xuan Yang; Min Qui; Andrey A. Ivanov; Yuhong Du; Haian Fu. "Hypomorph Mutation-Directed Small-Molecule Protein-Protein Interaction Inducers to Restore Mutant SMAD4-Suppressed TGF-ß Signaling". Cell Chemical Biology (2020): https://doi.org/10.1016/j.chembiol.2020.11.010.
    10.1016/j.chembiol.2020.11.010
  11. Tang, Cong. "Transcriptional regulation of FoxM1 by HIF-1a mediates hypoxia-induced EMT in prostate cancer". Oncology Reports (2019): http://dx.doi.org/10.3892/or.2019.7248.
    10.3892/or.2019.7248
  12. Tang, Cong. "Classic and Novel Signaling Pathways Involved in Cancer: Targeting the NF-¿B and Syk Signaling Pathways". Current Stem Cell Research & Therapy (2019): http://dx.doi.org/10.2174/1574888x13666180723104340.
    10.2174/1574888x13666180723104340
  13. Tang, Cong. "HTiP: High-Throughput Immunomodulator Phenotypic Screening Platform to Reveal IAP Antagonists as Anti-cancer Immune Enhancers". Cell Chemical Biology (2019): http://dx.doi.org/10.1016/j.chembiol.2018.11.011.
    10.1016/j.chembiol.2018.11.011
  14. Tang, Cong. "Large tumor suppressor 2, LATS2, activates JNK in a kinase-independent mechanism through ASK1". Journal of Molecular Cell Biology (2018): http://dx.doi.org/10.1093/jmcb/mjy061.
    10.1093/jmcb/mjy061
  15. Tang, Cong. "The clinical significance of vasculogenic mimicry and expression of VE-cadherin in patients with clear cell renal cell carcinoma". ¿¿¿¿¿¿¿¿ 9 (2017): https://www.cnki.com.cn/Article/CJFDTotal-MNWK201709007.htm.
    10.3969/j.issn.1009-8291.2017.09.006
  16. Tang, Cong. "Surgical treatment of 137 cases of pheochromocytoma/paraganglioma: outcome analysis and clinical experience from a single institution". ¿¿¿¿¿¿¿¿ 8 (2017): https://www.cnki.com.cn/Article/CJFDTotal-MNWK201708010.htm.
    10.3969/j.issn.1009-8291.2017.08.008
  17. Tang, Cong. "Research progress on malignant evolution of angiogenic mimicry and renal cell carcinoma". ¿¿¿¿¿¿¿¿ 4 (2017): https://www.cnki.com.cn/Article/CJFDTotal-MNWK201704020.htm.
    10.3969/j.issn.1009-8291.2017.04.017
  18. Tang, Cong. "Application of PBL teaching method combined with literature retrieval in clinical practice teaching of urology". ¿¿ 2 (2017): https://www.cnki.com.cn/Article/CJFDTotal-XBYX201702047.htm.
    10.13555/j.cnki.c.m.e.2017.02.044
Pré-impressão
  1. "Systematic discovery of mutation-directed neo-protein-protein interactions in cancer". 2021. http://dx.doi.org/10.1101/2021.10.03.462422.
    10.1101/2021.10.03.462422

Propriedade Intelectual

Patente
  1. 2021. "Small Molecule Inducer of SMAD4 Complex for Cancer Therapy". Estados Unidos.
    Permitida
  2. Tang, Cong. 2020. "KRAS G12V Mutant Binds to JAK1, Inhibitors, Pharmaceutical Compositions, and Methods Related Thereto".
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2021/11/11 Discovery of hypomorph mutation-directed small molecule protein-protein interaction inducers/molecular glues ICBS2021
Emory University (Atlanta, Estados Unidos)
2021/10/13 Potential of natural product-- Piperlongumine against SARS-CoV-2 ACORN
(algarve, Portugal)
2020/10/19 E3-hijacking molecular glues of RNA binding protein IGF2BP1 in ovarian cancer ACORN
(algarve, Portugal)

Participação em evento

Descrição da atividade
Tipo de evento 		Nome do evento
Instituição / Organização
2021/09/29 - Atual NL-CVX1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Concern
Conferência
 IDWeek 2021
2019/04/06 - 2019/04/09 Attended 2019 ASPET Annual Meeting at EB (Experimental Biology) at Orlando, Florida.
Conferência
 2019 ASPET Annual Meeting

Entrevista (jornal / revista)

Descrição da atividade Jornal / Forum
2020/12/15 finding a small-molecule compound that corrects a defective protein-protein interaction Lab Land-The Emory Health Science Research Blog
2019/01/10 Uncovering more options in cancer immunotherapy Emory New's Center